Tremeau Pharmaceuticals focuses on orphan or unique disease states with a high unmet medical need for which there are no approved treatments.

Tremeau currently has two development programs outlined below.
 

TRM - 201 (Rofecoxib)

TRM - 201 (rofecoxib) is being developed as a fast-track, first approved treatment for Hemophilic Arthropathy, a serious orphan disease for which high-potency opioids are the current standard of care.

 

TRM - 359 (Etoricoxib)

TRM - 359 (etoricoxib) is being developed as a breakthrough, first approved treatment for a serious pediatric orphan disease for which high-potency opioid therapies are the only available therapies.